The global deep brain stimulators (DBS) market was valued at USD 618.6 million in 2014 and is expected to grow at CAGR of above 17.0% over the forecast period. Growing adoption of DBS for the treatment of various neurological disorders including obsessive-compulsive disorder (OCD), Parkinson’s diseases, Dystonia, essential tremor, Epilepsy and Alzheimer’s disease is a key growth driver of this market. Additionally, rising geriatric population prone to neurological diseases coupled with the availability of technologically advanced & cost efficient technology for the treatment is expected to fuel growth over the forecast period.
Increasing R&D pertaining to deep brain stimulators, the introduction of technologically advanced product including electric current fractionated implantable pulse generator (IPG), are also expected to propel overall industry growth in near future. IPG enables variable electric current proportions between multi polar lead and on demand stimulation in the treatment. Computer-based feedback signal are helpful in increasing treatment efficiency and minimize the side effects. These aforementioned factors are anticipated to provide this industry with lucrative growth opportunities.
According to Parkinson’s disease Foundation, the incidences of Parkinson’s disease increases with an old age and the median age of this disease is 55 to 60. Rising incidences of target diseases is a notable impact rendering growth driver for deep brain stimulators industry. The inadequacy of oral therapeutics such as dopamine for the neurological diseases treatment and side effects are responsible for increasing adoption of nonconventional DBS treatment, is expected to serve this industry with further growth opportunities.
U.S. deep brain stimulators market, by application, 2012-2020 (USD Million)
Parkinson’s disease is most commonly treated by deep brain stimulators as it helps in keeping track of short-lived symptom fluctuations in disease progression. It is more effective than other oral treatment options, which is responsible for the largest market share of this segment and is expected to grow at CAGR of over 16.0% over the forecast period. Obsessive compulsive disorder (OCD) and Dystonia segments follow Parkinson’s disease in terms of revenue.
It is preferred over the conventional medication therapy owing to the benefits attached such as reduced medication dosage, low risk of medicine induced side effect such as Dyskinesia, improved motor symptoms for comparatively longer period of time and relief from nonmotor symptoms including muscle cramps and sleep disturbance. Deep brain stimulator is also found to be instrumental in providing enhanced life quality by improving motor symptoms. The above-mentioned factors are responsible for the growth of DBS during the forecast period.
It also finds application in pain management. CE certification for usage of deep brain stimulation in the treatment of Epilepsy in Europe is expected to drive regional market growth in near future. Research work for enabling use of DBS for all these applications are in progress which is further expected to fuel the demand for deep brain stimulators.
North America dominated the overall industry in terms of revenue in 2014 at over 54.0%. The dominance is attributed to the factors including the presence of favorable reimbursement policies and sophisticated healthcare infrastructure. Increasing awareness pertaining to its applications and associated benefits with it are the factors contributing to the largest share of this region.
Furthermore, pending commercialization approval by U.S. FDA for the use of DBS in the treatment of Epilepsy is further expected to strengthen the consumer base in this region. On the contrary, increasing patient awareness levels coupled with growing disposable income & healthcare expenditure in the emerging economies such as India and China is expected to provide remunerative growth platform to Asia Pacific regional market over the forecast period.
Competitive Market Share Insights
The key players of this industry include Medtronic Plc, St. Jude Medical Inc., Boston Scientific, and Aleva Neurotherapeutics SA. The market is oligopolistic in nature and companies are focusing on providing technologically advanced products to gain competitive advantage & striving to increase penetration. Key strategies adopted by manufacturers include promotional campaigns, to increase awareness levels of healthcare professionals and patients pertaining to DBS which would be helpful in increasing acceptance of the therapy in near future.
Grand View Research offers special pricing for:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.